Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002009910 | SCV002261239 | uncertain significance | not provided | 2022-06-20 | criteria provided, single submitter | clinical testing | The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C15"). This variant has not been reported in the literature in individuals affected with DVL1-related conditions. This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 128 of the DVL1 protein (p.Arg128Cys). |
Fulgent Genetics, |
RCV002492221 | SCV002804014 | uncertain significance | Autosomal dominant Robinow syndrome 1; Autosomal dominant Robinow syndrome 2 | 2021-12-10 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004976059 | SCV005576440 | uncertain significance | Inborn genetic diseases | 2024-11-11 | criteria provided, single submitter | clinical testing | The c.382C>T (p.R128C) alteration is located in exon 4 (coding exon 4) of the DVL1 gene. This alteration results from a C to T substitution at nucleotide position 382, causing the arginine (R) at amino acid position 128 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |